Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Beijing Tiantan Hospital
Modality
monoclonal_antibody
Development Phase
Unknown
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05334927CT.gov China HeadAche DIsorders RegiStry | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Trigeminal Autonomic Cephalalgia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eptinezumab (this asset) | Beijing Tiantan Hospital | Unk | D · 30 |
| Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer | Beijing Tiantan Hospital | P2 | B |
| Marcaine | Stanford University | P2 | CCC |
| Capsaicin | The University of Texas Health Science Center, Houston | P1 | CC |
| AIR | The University of Texas Health Science Center, Houston | P1 | CC |
| Oxygen | The University of Texas Health Science Center, Houston | P1 | CC |
| Yangxue Qingnao Granules | Beijing Tiantan Hospital | Unk | D |
Other indications for Eptinezumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P4 | BBB · 79 |
| Tinnitus | — | P4 | B · 62 |
| Migraine Without Aura | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, DimerBeijing Tiantan HospitalB
- MarcaineStanford UniversityCCC
- CapsaicinThe University of Texas Health Science Center, HoustonCC
- AIRThe University of Texas Health Science Center, HoustonCC
- OxygenThe University of Texas Health Science Center, HoustonCC
Citation
Floatz Terminal. Eptinezumab in Trigeminal Autonomic Cephalalgia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eptinezumab-trigeminal-autonomic-cephalalgia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →